The specificity of G9a expression compared to normal plasma cells as well as the minimal effects of G9a inhibition on normal lymphocyte development further emphasize the attractiveness of targeting G9a in multiple myeloma. This evidence concerns the gene EHMT2 and plasma cell myeloma.